Intech Investment Management LLC Grows Position in United Therapeutics Corporation $UTHR

Intech Investment Management LLC raised its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 3.6% during the 2nd quarter, Holdings Channel.com reports. The fund owned 32,056 shares of the biotechnology company’s stock after acquiring an additional 1,121 shares during the period. Intech Investment Management LLC’s holdings in United Therapeutics were worth $9,211,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of UTHR. Denali Advisors LLC lifted its position in shares of United Therapeutics by 7.1% during the first quarter. Denali Advisors LLC now owns 1,503 shares of the biotechnology company’s stock valued at $463,000 after purchasing an additional 100 shares in the last quarter. South Dakota Investment Council boosted its holdings in United Therapeutics by 2.1% during the first quarter. South Dakota Investment Council now owns 9,838 shares of the biotechnology company’s stock worth $3,033,000 after purchasing an additional 200 shares during the last quarter. AustralianSuper Pty Ltd grew its position in United Therapeutics by 49.0% in the 1st quarter. AustralianSuper Pty Ltd now owns 282,739 shares of the biotechnology company’s stock worth $87,160,000 after purchasing an additional 92,959 shares in the last quarter. IFP Advisors Inc increased its stake in United Therapeutics by 103.4% in the 1st quarter. IFP Advisors Inc now owns 1,739 shares of the biotechnology company’s stock valued at $536,000 after buying an additional 884 shares during the last quarter. Finally, Allianz Asset Management GmbH lifted its position in shares of United Therapeutics by 96.9% during the 1st quarter. Allianz Asset Management GmbH now owns 67,576 shares of the biotechnology company’s stock worth $20,832,000 after buying an additional 33,254 shares in the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Stock Performance

UTHR stock opened at $466.40 on Friday. The stock has a fifty day moving average of $432.38 and a 200-day moving average of $349.68. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $479.50. The company has a market capitalization of $20.08 billion, a price-to-earnings ratio of 17.67, a PEG ratio of 4.96 and a beta of 0.77.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, beating the consensus estimate of $6.89 by $0.27. The business had revenue of $799.50 million for the quarter, compared to the consensus estimate of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The company’s revenue was up 6.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $6.39 earnings per share. Equities analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current year.

Insider Buying and Selling at United Therapeutics

In related news, COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $452.07, for a total value of $10,171,575.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Martine A. Rothblatt sold 4,000 shares of United Therapeutics stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $460.00, for a total transaction of $1,840,000.00. Following the completion of the transaction, the chief executive officer owned 130 shares of the company’s stock, valued at $59,800. This represents a 96.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 471,435 shares of company stock valued at $200,294,552. 10.30% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on UTHR shares. Oppenheimer boosted their target price on United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a research note on Friday, September 5th. Cantor Fitzgerald boosted their price objective on United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 10th. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a research note on Wednesday, October 29th. Weiss Ratings reiterated a “buy (b-)” rating on shares of United Therapeutics in a research note on Thursday. Finally, UBS Group increased their price target on shares of United Therapeutics from $580.00 to $600.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $503.90.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.